홈 > 시장보고서 > 의료기기 > 수술관련기기

시장보고서

상품코드

2070312

치료용 이비인후과 기기 시장 규모와 예측(2021-2034년), 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 종류별, 용도별, 최종사용자별, 지역별

Therapeutic ENT Devices Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, End User, and Geography

발행일: 2026년 06월 | 리서치사: 구분자

The Insight Partners | 페이지 정보: 영문 299 Pages | 배송안내 : 즉시배송

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,928,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 10,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 13,155,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치료용 이비인후과 기기 시장 규모는 2025년 212억 3,000만 달러에서 2034년까지 129억 7,000만 달러로 확대될 것으로 예상되고, 2026년부터 2034년까지 CAGR 5.6%를 기록할 것으로 전망됩니다.

청력 손실 및 이비인후과 질환의 부담 증가, 만성 부비동염 및 알레르기성 비염의 유병률 상승, 고령 인구 확대는 치료용 이비인후과 기기 시장의 성장에 기여하는 주목할 만한 요인입니다. 또한, 노화에 따른 이비인후과 질환의 발병과 질환의 조기 발견에 대한 관심이 높아짐에 따라, 가까운 시일 내에 시장에 새로운 동향이 나타날 것으로 예상됩니다.

세계보건기구(WHO)의 '세계 청각 보고서'(2021년, 2023년 업데이트된 정책 개요)에 따르면, 현재 전 세계적으로 4억 3,000만 명 이상이 일상생활에 지장을 줄 정도의 난청을 앓으며 살고 있습니다. 이 수치는 인구 동향과 환경적 요인에 따라 향후 수십 년 동안 증가할 것으로 예상됩니다.

미국에서는 질병통제예방센터(CDC)가 “국민 건강·영양 조사(NHANES 2023-2024년 개정판)”에 따르면, 12세 이상 인구의 약 13%가 양쪽 귀에 난청을 앓고 있으며, 60세 이상 성인의 경우 그 유병률이 급격히 증가하고 있다고 보고하고 있습니다.

미국 고령층의 경우, CDC 자료에 따르면 65세에서 74세 사이의 약 3명 중 1명이 난청을 겪고 있는 것으로 나타나, 노화에 따른 치료적 개입에 대한 수요가 높다는 사실이 부각되고 있습니다.

인도에서는 보건가족복지부(MoHFW)가 “청력 손실 예방 및 관리 국가 프로그램(NPPCD)”의 2023-2024년도 보고서에 따르면, 인도 내에서 6,300만 명 이상이 심각한 청각 장애로 고통받고 있는 것으로 추정되며, 1차 의료 현장에서의 선별 검사 프로그램 확대에 따라 장애 발견률은 증가 추세를 보이고 있습니다.

유럽에서는 유럽연합 집행위원회의 'Health at a Glance : Europe 2024'에 따르면, 인구의 약 20%가 어느 정도의 청각 장애를 겪고 있으며, 70세 이상 인구의 유병률은 30%를 초과하고 있습니다.

이러한 역학적 추세에 따라 인공 와우, 골전도형 보청기 시스템, 첨단 청각 재활 기술 등 치료용 이비인후과 기기에 대한 수요가 증가하고 있습니다. 미국 식품의약국(FDA)은 2023년부터 2025년까지 신호 처리 성능 향상, 소형화, 무선 통합을 특징으로 하는 차세대 인공와우 시스템을 승인했습니다.

이처럼 전 세계적인 유병률 증가, 노화에 따른 청력 저하, 그리고 규제 당국의 지원을 받은 기술 혁신이 치료용 이비인후과 기기 시장의 성장을 이끄는 주요 요인으로 작용하고 있습니다.

용도별 채널 분석

용도별 시장 세분화에서는 시장이 이비인후과, 비과, 후두과 및 기타 용도로 분류됩니다. 2025년에는 병원 약국 부문이 가장 큰 시장 점유율을 차지했습니다. 치료용 이비인후과 기기 시장의 이과학 부문은 청력 손실 유병률의 증가, 만성 중이염으로 인한 부담의 확대, 그리고 외과적 및 이식형 귀 재활 기술에 대한 수요 증가에 힘입어 성장하고 있습니다. WHO 기준에 따른 역학적 추산(2024-2025년)에 따르면, 전 세계적으로 4억 6,600만 명 이상이 일상생활에 지장을 주는 청력 손실을 겪고 있으며, 그 유병률은 고령화 사회에서 현저히 증가하고 있습니다. 65세 이상 개인 중, 연령대에 따라 최대 18%에서 77%가 어느 정도의 청력 장애를 겪고 있습니다.

CDC가 지원하는 이비인후과 질환 부담 데이터(2023-2024년)에 따르면, 만성 중이염은 전 세계적으로, 특히 소아 인구에서 예방 가능한 난청의 주요 원인 중 하나로 계속해서 꼽히고 있으며, 고막 성형술, 유돌절제술, 그리고 관련 이과적 시술에 대한 수요를 이끌고 있습니다.

동료 심사를 거친 이비인후과 외과 문헌(2024-2025년)에 따르면, 적응증 확대와 수술 후 예후 개선으로 인해 인공와우 이식 및 중이 재건 수술이 계속 증가하고 있으며, 전 세계 누적 인공와우 이식 수술 건수가 100만 건을 넘어섰으며, 성인 및 소아 모두에서 연간 이식률이 상승하고 있습니다.

WHO의 신생아 청력 선별 검사 지침(2023-2025년 개정판)에 따르면, 선천성 난청은 출생아 1,000명당 1-3명에게 영향을 미치고 있으며, 이는 조기 이비인후과적 개입에 대한 필요성을 더욱 강조하고 있습니다.

또한, 2023년부터 2025년까지 최소침습 이비인후과 수술, 로봇 보조 이비인후과 수술, 그리고 차세대 인공와우 시스템의 발전으로 인해 청각 재활의 성과가 크게 향상되었습니다. 전반적으로, 질병 부담의 증가, 고령화, 그리고 이비인후과 수술 분야의 기술 혁신이 진행되고 있습니다.

The rising burden of hearing loss and otologic disorders, the increasing incidence of chronic sinusitis and allergic rhinitis, the expansion of the geriatric population are noteworthy factors contributing to the expansion of the Therapeutic ENT Devices market. Additionally, the development of age-related ENT disorders as well as growing focus on early disease detection are projected to bring new market drifts in the near future.

According to the World Health Organization (WHO) in its World Report on Hearing (2021, updated policy briefs 2023), more than 430 million people globally currently live with disabling hearing loss. This number is projected to rise in the coming decades due to demographic and environmental factors.

In the US, the Centers for Disease Control and Prevention (CDC), based on the National Health and Nutrition Examination Survey (NHANES 2023-2024 updates), reports that approximately 13% of individuals aged 12 and older have bilateral hearing loss, with prevalence rising sharply among adults aged 60 and above.

Among older adults in the US, CDC data indicate that nearly 1 in 3 people aged 65-74 experience hearing loss, highlighting strong age-linked demand for therapeutic interventions.

In India, the Ministry of Health and Family Welfare (MoHFW), through the National Programme for Prevention and Control of Deafness (NPPCD) 2023-2024 report, estimated that over 63 million people in India are affected by significant auditory impairment, with increasing identification rates due to expanded screening programs in primary healthcare settings.

In Europe, according to the European Commission's Health at a Glance: Europe 2024, approximately 20% of the population reports some degree of hearing disability, with prevalence exceeding 30% among individuals above 70.

These epidemiological trends are increasing demand for therapeutic ENT devices such as cochlear implants, bone-anchored hearing systems, and advanced auditory rehabilitation technologies. The U.S. Food and Drug Administration (FDA) approved next-generation cochlear implant systems between 2023 and 2025, featuring improved signal processing, miniaturization, and wireless integration.

Thus, rising global prevalence, aging-related auditory decline, and regulatory-backed technological innovation are key factors driving the growth of the therapeutic ENT devices market.

Application Channel -Based Insights

By application, the market is segmented into otology, rhinology, laryngology, and other applications. The hospital pharmacy segment held the largest market share in 2025. The otology segment in the therapeutic ENT devices market is growing due to the rising prevalence of hearing loss, increasing burden of chronic otitis media, and expanding demand for surgical and implantable ear rehabilitation technologies. According to WHO-aligned epidemiological estimates (2024-2025), more than 466 million people globally live with disabling hearing loss, with prevalence increasing significantly in aging populations where up to 18%-77% of individuals above 65 years experience some degree of hearing impairment depending on age subgroup.

According to CDC-supported ENT burden data (2023-2024), chronic otitis media remains one of the leading causes of preventable hearing loss worldwide, particularly in pediatric populations, driving demand for tympanoplasty, mastoidectomy, and related otologic interventions.

According to peer-reviewed otology surgical literature (2024-2025), cochlear implantation and middle ear reconstruction procedures continue to increase due to improved candidacy expansion and better post-surgical outcomes, with over 1 million cochlear implant procedures performed globally cumulatively and rising annual implantation rates in both adults and children.

According to WHO newborn hearing screening frameworks (2023-2025 updates), congenital hearing loss affects 1-3 per 1,000 live births, reinforcing early otologic intervention demand.

Additionally, advancements between 2023 and 2025 in minimally invasive ear surgery, robotic-assisted otologic procedures, and next-generation cochlear implant systems have significantly improved auditory rehabilitation outcomes. Overall, rising disease burden, aging populations, and technological innovation in ear surgery.

The World Health Organization, Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Functional Endoscopic Sinus Surgery (FESS), Health Sciences Authority, the Italian National Institute of Statistics (ISTAT), South Korea Food and Drug Administration (KFDA), the European Hearing Instrument Manufacturers Association (EHIMA) are among the primary and secondary sources referred to while preparing the Therapeutic ENT Devices market report.

1. Executive Summary

1.1 Analyst Market Outlook
1.2 Market Attractiveness

2. Therapeutic ENT Market to 2034 Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Force Analysis
2.5 PEST Analysis
2.6 Import-Export Analysis for Key Countries (As per the nearest HS Code)
- 2.6.1 Import-Export Analysis for Key Countries
2.7 Impact of Artificial Intelligence (AI)
2.8 Product or Technology Roadmap
2.9 Sustainability and ESG Trends
2.10 Patent Analysis
2.11 Regulatory Framework

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Therapeutic ENT Market to 2034 - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints

5. Therapeutic ENT Market to 2034 - Global Market Analysis

5.1 Therapeutic ENT Market to 2034 Revenue (US$ Million), 2021-2034
5.2 Therapeutic ENT Market to 2034 Forecast and Analysis

6. Therapeutic ENT Market to 2034 Revenue Analysis - Type

6.1 Therapeutic ENT Market to 2034 Forecasts and Analysis by Type
- 6.1.1 Hearing Aids and Cochlear Implants
  - 6.1.1.1 Overview
  - 6.1.1.2 Hearing Aids and Cochlear Implants: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 6.1.2 Bone-Anchored Hearing Systems
  - 6.1.2.1 Overview
  - 6.1.2.2 Bone-Anchored Hearing Systems: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 6.1.3 Voice Prostheses
  - 6.1.3.1 Overview
  - 6.1.3.2 Voice Prostheses: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 6.1.4 Nasal Splints and Airway Stents
  - 6.1.4.1 Overview
  - 6.1.4.2 Nasal Splints and Airway Stents: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 6.1.5 Epistaxis Management Devices
  - 6.1.5.1 Overview
  - 6.1.5.2 Epistaxis Management Devices: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 6.1.6 Nebulizers and Drug-Delivery Systems for ENT Disorders
  - 6.1.6.1 Overview
  - 6.1.6.2 Nebulizers and Drug-Delivery Systems for ENT Disorders: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)

7. Therapeutic ENT Market to 2034 Revenue Analysis - Application

7.1 Therapeutic ENT Market to 2034 Forecasts and Analysis by Application
- 7.1.1 Otology
  - 7.1.1.1 Overview
  - 7.1.1.2 Otology: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 7.1.2 Rhinology
  - 7.1.2.1 Overview
  - 7.1.2.2 Rhinology: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 7.1.3 Laryngology
  - 7.1.3.1 Overview
  - 7.1.3.2 Laryngology: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 7.1.4 Other Applications
  - 7.1.4.1 Overview
  - 7.1.4.2 Other Applications: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)

8. Therapeutic ENT Market to 2034 Revenue Analysis - End User

8.1 Therapeutic ENT Market to 2034 Forecasts and Analysis by End User
- 8.1.1 Hospitals
  - 8.1.1.1 Overview
  - 8.1.1.2 Hospitals: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 8.1.2 Ambulatory Surgical Centers (ASC)
  - 8.1.2.1 Overview
  - 8.1.2.2 Ambulatory Surgical Centers (ASC): Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 8.1.3 ENT Specialty Clinics
  - 8.1.3.1 Overview
  - 8.1.3.2 ENT Specialty Clinics: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 8.1.4 Home Healthcare
  - 8.1.4.1 Overview
  - 8.1.4.2 Home Healthcare: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)
- 8.1.5 Other End Users
  - 8.1.5.1 Overview
  - 8.1.5.2 Other End Users: Therapeutic ENT Market to 2034 - Revenue, 2021-2034 (US$ Million)

9. Therapeutic ENT Market to 2034 - Geographical Analysis

9.1 North America
- 9.1.1 North America Therapeutic ENT Market to 2034 Overview
- 9.1.2 North America: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.1.3 North America: Therapeutic ENT Market to 2034 - By Segmentation
  - 9.1.3.1 Type
  - 9.1.3.2 Application
  - 9.1.3.3 End User
- 9.1.4 North America: Therapeutic ENT Market to 2034 Breakdown by Countries
  - 9.1.4.1 United States Market
    - 9.1.4.1.1 United States: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.1.4.1.2 United States: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.1.4.1.2.1 Type
      - 9.1.4.1.2.2 Application
      - 9.1.4.1.2.3 End User
  - 9.1.4.2 Canada Market
    - 9.1.4.2.1 Canada: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.1.4.2.2 Canada: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.1.4.2.2.1 Type
      - 9.1.4.2.2.2 Application
      - 9.1.4.2.2.3 End User
  - 9.1.4.3 Mexico Market
    - 9.1.4.3.1 Mexico: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.1.4.3.2 Mexico: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.1.4.3.2.1 Type
      - 9.1.4.3.2.2 Application
      - 9.1.4.3.2.3 End User
9.2 Europe
- 9.2.1 Europe Therapeutic ENT Market to 2034 Overview
- 9.2.2 Europe: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.2.3 Europe: Therapeutic ENT Market to 2034 - By Segmentation
  - 9.2.3.1 Type
  - 9.2.3.2 Application
  - 9.2.3.3 End User
- 9.2.4 Europe: Therapeutic ENT Market to 2034 Breakdown by Countries
  - 9.2.4.1 Germany Market
    - 9.2.4.1.1 Germany: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.1.2 Germany: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.1.2.1 Type
      - 9.2.4.1.2.2 Application
      - 9.2.4.1.2.3 End User
  - 9.2.4.2 United Kingdom Market
    - 9.2.4.2.1 United Kingdom: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.2.2 United Kingdom: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.2.2.1 Type
      - 9.2.4.2.2.2 Application
      - 9.2.4.2.2.3 End User
  - 9.2.4.3 France Market
    - 9.2.4.3.1 France: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.3.2 France: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.3.2.1 Type
      - 9.2.4.3.2.2 Application
      - 9.2.4.3.2.3 End User
  - 9.2.4.4 Italy Market
    - 9.2.4.4.1 Italy: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.4.2 Italy: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.4.2.1 Type
      - 9.2.4.4.2.2 Application
      - 9.2.4.4.2.3 End User
  - 9.2.4.5 Spain Market
    - 9.2.4.5.1 Spain: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.5.2 Spain: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.5.2.1 Type
      - 9.2.4.5.2.2 Application
      - 9.2.4.5.2.3 End User
  - 9.2.4.6 Rest of Europe Market
    - 9.2.4.6.1 Rest of Europe: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.6.2 Rest of Europe: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.2.4.6.2.1 Type
      - 9.2.4.6.2.2 Application
      - 9.2.4.6.2.3 End User
9.3 Asia Pacific
- 9.3.1 Asia Pacific Therapeutic ENT Market to 2034 Overview
- 9.3.2 Asia Pacific: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.3.3 Asia Pacific: Therapeutic ENT Market to 2034 - By Segmentation
  - 9.3.3.1 Type
  - 9.3.3.2 Application
  - 9.3.3.3 End User
- 9.3.4 Asia Pacific: Therapeutic ENT Market to 2034 Breakdown by Countries
  - 9.3.4.1 China Market
    - 9.3.4.1.1 China: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.1.2 China: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.1.2.1 Type
      - 9.3.4.1.2.2 Application
      - 9.3.4.1.2.3 End User
  - 9.3.4.2 Japan Market
    - 9.3.4.2.1 Japan: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.2.2 Japan: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.2.2.1 Type
      - 9.3.4.2.2.2 Application
      - 9.3.4.2.2.3 End User
  - 9.3.4.3 India Market
    - 9.3.4.3.1 India: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.3.2 India: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.3.2.1 Type
      - 9.3.4.3.2.2 Application
      - 9.3.4.3.2.3 End User
  - 9.3.4.4 Australia Market
    - 9.3.4.4.1 Australia: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.4.2 Australia: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.4.2.1 Type
      - 9.3.4.4.2.2 Application
      - 9.3.4.4.2.3 End User
  - 9.3.4.5 South Korea Market
    - 9.3.4.5.1 South Korea: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.5.2 South Korea: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.5.2.1 Type
      - 9.3.4.5.2.2 Application
      - 9.3.4.5.2.3 End User
  - 9.3.4.6 Rest of Asia Pacific Market
    - 9.3.4.6.1 Rest of Asia Pacific: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.6.2 Rest of Asia Pacific: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.3.4.6.2.1 Type
      - 9.3.4.6.2.2 Application
      - 9.3.4.6.2.3 End User
9.4 Middle East and Africa
- 9.4.1 Middle East and Africa Therapeutic ENT Market to 2034 Overview
- 9.4.2 Middle East and Africa: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.4.3 Middle East and Africa: Therapeutic ENT Market to 2034 - By Segmentation
  - 9.4.3.1 Type
  - 9.4.3.2 Application
  - 9.4.3.3 End User
- 9.4.4 Middle East and Africa: Therapeutic ENT Market to 2034 Breakdown by Countries
  - 9.4.4.1 Saudi Arabia Market
    - 9.4.4.1.1 Saudi Arabia: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.4.4.1.2 Saudi Arabia: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.4.4.1.2.1 Type
      - 9.4.4.1.2.2 Application
      - 9.4.4.1.2.3 End User
  - 9.4.4.2 South Africa Market
    - 9.4.4.2.1 South Africa: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.4.4.2.2 South Africa: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.4.4.2.2.1 Type
      - 9.4.4.2.2.2 Application
      - 9.4.4.2.2.3 End User
  - 9.4.4.3 United Arab Emirates Market
    - 9.4.4.3.1 United Arab Emirates: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.4.4.3.2 United Arab Emirates: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.4.4.3.2.1 Type
      - 9.4.4.3.2.2 Application
      - 9.4.4.3.2.3 End User
  - 9.4.4.4 Rest of Middle East and Africa Market
    - 9.4.4.4.1 Rest of Middle East and Africa: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.4.4.4.2 Rest of Middle East and Africa: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.4.4.4.2.1 Type
      - 9.4.4.4.2.2 Application
      - 9.4.4.4.2.3 End User
9.5 South and Central America
- 9.5.1 South and Central America Therapeutic ENT Market to 2034 Overview
- 9.5.2 South and Central America: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.5.3 South and Central America: Therapeutic ENT Market to 2034 - By Segmentation
  - 9.5.3.1 Type
  - 9.5.3.2 Application
  - 9.5.3.3 End User
- 9.5.4 South and Central America: Therapeutic ENT Market to 2034 Breakdown by Countries
  - 9.5.4.1 Brazil Market
    - 9.5.4.1.1 Brazil: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.5.4.1.2 Brazil: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.5.4.1.2.1 Type
      - 9.5.4.1.2.2 Application
      - 9.5.4.1.2.3 End User
  - 9.5.4.2 Argentina Market
    - 9.5.4.2.1 Argentina: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.5.4.2.2 Argentina: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.5.4.2.2.1 Type
      - 9.5.4.2.2.2 Application
      - 9.5.4.2.2.3 End User
  - 9.5.4.3 Rest of South and Central America Market
    - 9.5.4.3.1 Rest of South and Central America: Therapeutic ENT Market to 2034 Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.5.4.3.2 Rest of South and Central America: Therapeutic ENT Market to 2034 - By Segmentation
      - 9.5.4.3.2.1 Type
      - 9.5.4.3.2.2 Application
      - 9.5.4.3.2.3 End User

10. Therapeutic ENT Market to 2034 Industry Landscape

11. Therapeutic ENT Market to 2034 - Key Company Profiles

11.1 Sonova Holding AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 GN Store Nord AS
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Cochlear Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 WS Audiology AS
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Stryker Corp
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Karl Storz SE & Co KG
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Smith & Nephew Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Demant AS
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Medtronic Plc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Olympus Corp
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. List of Additional Companies Analyzed

12.1 List of Additional Companies Analyzed

13. Appendix

13.1 Glossary
13.2 Research Methodology and Approach
- 13.2.1 Secondary Research
- 13.2.2 Primary Research
- 13.2.3 Market Estimation Approach
  - 13.2.3.1 Supply Side Analysis
  - 13.2.3.2 Demand Side Analysis
- 13.2.4 Research Assumptions and Limitations
- 13.2.5 Currency Conversion
13.3 About The Insight Partners
13.4 Market Intelligence Cloud

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,928,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 10,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 13,155,000

※ 부가세 별도

검색

F A Q

치료용 이비인후과 기기 시장 규모와 예측(2021-2034년), 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 종류별, 용도별, 최종사용자별, 지역별

Therapeutic ENT Devices Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, End User, and Geography

목차

제1장 주요 요약

제2장 2034년까지 치료용 이비인후과 시장 전망과 시장 구도

제3장 경쟁 구도

제4장 치료용 이비인후과 기기 시장 - 주요 시장 역학

제5장 치료용 이비인후과 기기 시장 - 세계 시장 분석

제6장 2034년까지 치료용 이비인후과 시장 매출 분석 : 종류별

제7장 치료용 이비인후과 기기 시장 매출 분석 : 용도별

제8장 2034년까지 치료용 이비인후과 시장 매출 분석 : 최종사용자

제9장 치료용 이비인후과 기기 시장 - 지역 분석

제10장 2034년까지 치료용 이비인후과 시장 : 업계 상황

제11장 치료용 이비인후과 기기 시장 - 주요 기업 개요

제12장 기타 분석 대상 기업 리스트

제13장 부록